Special Drug Use-results Surveillance of Tabrecta Tablets

Special Drug Use-results Surveillance of Tabrecta Tablets (MET Exon 14 Skipping Mutation-positive Unresectable Advanced/Recurrent Non-small Cell Lung Cancer)

ClinicalTrials.gov Identifier: NCT04575025

Novartis Reference Number: CINC280AJP01

See if you pre-qualify

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation. 

Study Description

This study is an uncontrolled, primary data collection-based observational study to be conducted as a central registration system, multicenter special drug-use results surveillance. As an all-case study, this study will collect all patients treated with Tabrecta in a specified post-marketing period. The observation period of each patient is up to 1 year (52 weeks)

Condition 
Non-small Cell Lung Cancer
Phase 
Not Given
Overall status 
Not yet recruiting
Enrollment count 
100 participants
Start date 
Nov 30, 2020
Completion date 
Sep 29, 2023
Gender 
All
Age(s)
100 Years and older (Child, Adult, Older Adult)

Interventions

Drug
Tabrecta tablets
There is no treatment allocation. Patients administered Tabrecta by prescription that have started before inclusion of the patient into the study will be enrolled.

Eligibility Criteria

Inclusion Criteria:

All patients receiving Tabrecta for MET exon 14 skipping mutation-positive unresectable advanced/recurrent NSCLC during a specified post-marketing period

Exclusion Criteria:

-

Contacts

Name: 
Novartis Pharmaceuticals
Phone: 
+81337978748
Name: 
Novartis Pharmaceuticals
Phone: 
Email: 

Have a question?

Call 1-999-669-6682 or email [email protected]